Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AD 214

Next Previous
Drug Profile

AD 214

Alternative Names: AD-214; i-body based therapeutics - AdAlta

Latest Information Update: 22 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AdAlta
  • Developer AdAlta; The Alfred Hospital
  • Class Antifibrotics; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis; Interstitial lung diseases; Renal failure
  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 09 Feb 2024 AdAlta completes a phase-I clinical trials in Renal failure in Australia (IV) (NCT05914909)
  • 10 Aug 2023 Phase-I clinical trials in Renal failure in Australia (IV) (NCT05914909)
  • 10 Aug 2023 AdAlta initiates enrolment in a phase I extension trial for Interstitial lung disease or Chronic kidney disease in Australia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top